Working…
Help guide our efforts to modernize ClinicalTrials.gov.
Send us your comments by March 14, 2020.
ClinicalTrials.gov
ClinicalTrials.gov Menu

Randomised, Controlled Trial of an Individual Deprescribing Intervention for Nursing Homes Residents (OLD-NH-IDeI)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT03655405
Recruitment Status : Completed
First Posted : August 31, 2018
Last Update Posted : October 17, 2019
Sponsor:
Information provided by (Responsible Party):
Anne Niquille, University of Geneva, Switzerland

Brief Summary:
This study will evaluate the effects of a pharmacist-led, deprescribing-focused medication review on the use of inappropriate medications by nursing home residents

Condition or disease Intervention/treatment Phase
Polypharmacy Inappropriate Prescribing Other: Individual Deprescribing Intervention Not Applicable

Detailed Description:

Nursing home residents are often prescribed inappropriate medication, drugs whose negative effects outweigh potential benefits or which are not useful anymore. Inappropriate medication have been linked with worse health outcomes, hospitalisations and death. Deprescribing, the structured process of withdrawing or tapering inappropriate medications, has been studied as a potential solution to this problem.

In this study, nursing home residents living in institution which are already engaged in a deprescribing process will be randomly allocated to receive a medication review or usual care. The medication review will be performed by the nursing home pharmacist an its results will be discussed with the responsible physicians and nurses to create a deprescribing plan specifically tailored to the needs of the resident.

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 60 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Single (Outcomes Assessor)
Primary Purpose: Treatment
Official Title: Opportunities and Limits to Deprescribing in Nursing Homes: Randomised, Controlled Trial of an Individual Deprescribing Intervention for Nursing Homes Residents.
Actual Study Start Date : October 30, 2018
Actual Primary Completion Date : August 22, 2019
Actual Study Completion Date : August 22, 2019

Resource links provided by the National Library of Medicine

MedlinePlus related topics: Nursing Homes

Arm Intervention/treatment
Experimental: Intervention
Participants allocated to the intervention arm will receive the Individual Deprescribing Intervention (pharmacist-led medication review, followed by the creation of a deprescribing plan by the pharmacist, physician and responsible nurse).
Other: Individual Deprescribing Intervention
The pharmacist responsible for the nursing home will perform a medication review (type 3). The results of this review will be discussed with the physician and nurse responsible for this participant, with the goal of creating a personalised deprescribing plan. Once validated by the physician, this plan will be submitted to the participant for approval.

No Intervention: Control
Participants allocated to the control group will receive usual care.



Primary Outcome Measures :
  1. Change in the number of inappropriate medication between baseline and 4 months [ Time Frame: 4 months ]

Secondary Outcome Measures :
  1. Change between baseline and 4 months in the number of potentially inappropriate Defined Daily Doses (DDDs) prescribed to participants. [ Time Frame: 4 months ]
  2. Change between baseline and 4 months in the number of regular drugs prescribed to participants [ Time Frame: 4 months ]
  3. Change between baseline and 4 months in the number of regular DDDs prescribed to participants [ Time Frame: 4 months ]
  4. Number of new drugs prescribed as a result of the intervention [ Time Frame: 4 months ]
  5. Change in health-related quality of life between baseline and follow-up, measured with EQ-5D-5L [ Time Frame: 4 months ]
    The EQ-5D-5L (EuroQol 5-Dimension 5-Level) quality of life scale uses a questionnaire (5 questions) and a visual analog scale (0-100, higher score indicates better quality of life) to evaluate simply the respondent's perceived quality of life.

  6. Change in the number of common drug-related complaints presented by the participant between baseline and follow-up [ Time Frame: 4 months ]


Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   65 Years and older   (Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • Take 5 or more prescribed drugs daily;
  • Reside in the Nursing Home since at least 4 months.

Exclusion Criteria:

  • Physician judges that discussing deprescribing with them risks destabilising them.

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT03655405


Locations
Layout table for location information
Switzerland
Centre de Pharmacie Communautaire
Lausanne, Vaud, Switzerland, 1011
Sponsors and Collaborators
Anne Niquille
Investigators
Layout table for investigator information
Study Director: Olivier Bugnon, Prof ISPSO, Universties of Geneva and Lausanne, Switzerland
  Study Documents (Full-Text)

Documents provided by Anne Niquille, University of Geneva, Switzerland:

Additional Information:
Layout table for additonal information
Responsible Party: Anne Niquille, Doctor, University of Geneva, Switzerland
ClinicalTrials.gov Identifier: NCT03655405    
Other Study ID Numbers: OLD-NH-IDeI-2018
First Posted: August 31, 2018    Key Record Dates
Last Update Posted: October 17, 2019
Last Verified: October 2019
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: Undecided

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: No
Studies a U.S. FDA-regulated Device Product: No
Keywords provided by Anne Niquille, University of Geneva, Switzerland:
Deprescribing
Nursing Home
Potentially Inappropriate Medication